Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Patients presenting with motor deficits due to intraspinal tumor had excellent survival and favorable neurologic outcomes, with the majority reporting complete resolution of motor symptoms regardless of severity and duration of symptoms at diagnosis or neurosurgical intervention. Prompt diagnosis and initiation of first-line chemotherapy treatment remain priority, while neurosurgical intervention should be reserved for patients with rapid neurologic deterioration. Biology-based therapy and tumor response should continue to be used to maintain favorable outcomes.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2024-11-06
DOI
https://doi.org/10.1002/pbc.31407
Citations
1
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.37

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Arlene Naranjo, Wendy B. London, John M. Maris, Hiroyuki Shimada et al.
1 citations
Pediatric Blood & Cancer
Neuroblastoma Research and Treatments
0.37
article

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Arlene Naranjo, Wendy B. London, John M. Maris, Hiroyuki Shimada, Julie Voeller, Julie R. Park, Howard M. Katzenstein, Clare J. Twist, Susan L. Cohn, Rochelle Bagatell, Michael D. Hogarty, Sheena C. Tenney, Lulu Chen, Michael H. Handler, Julie Gastier‐Foster, Mary Lou Schmidt
article en
1 citations

Abstract

Patients presenting with motor deficits due to intraspinal tumor had excellent survival and favorable neurologic outcomes, with the majority reporting complete resolution of motor symptoms regardless of severity and duration of symptoms at diagnosis or neurosurgical intervention. Prompt diagnosis and initiation of first-line chemotherapy treatment remain priority, while neurosurgical intervention should be reserved for patients with rapid neurologic deterioration. Biology-based therapy and tumor response should continue to be used to maintain favorable outcomes.

Pediatric Blood & CancerVol. 72(1)
Roswell Park Comprehensive Cancer Center (US), St. Jude Children's Research Hospital (US), Lucile Packard Children's Hospital (US), Children's Hospital of Philadelphia (US), Harvard University (US), Baylor College of Medicine (US), University of Florida (US), University of Illinois Chicago (US), University of Chicago (US), Children's Hospital Colorado (US), Children's Oncology Group (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), University of Pennsylvania (US), University of Colorado Denver (US), Stanford University (US)
St. Baldrick's Foundation, National Institutes of Health, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 34%
Neuroblastoma Research and Treatments
0.37
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.